HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS

LATEST UPDATES » Vol 22, No 09, September 2018 – Doctor Robot - The digital healthcare revolution       » Gene helps rice adapt to colder climates       » 'Longevity protein' found effective in primates       » Korean beef inhibits proliferation of colorectal cancer cells       » First 3D printed human corneas       » Zombie gene protects against cancer in elephants      
INSIDE INDUSTRY
FDA approves sugar made from Brazil’s first genetically modified sugarcane
US FDA concludes review of sugar from the first GM sugarcane variety from Centro de Tecnologia Canavieira

The United States Federal Food and Drug Administration (FDA) concluded recently that raw and refined sugar produced from Brazil's first genetically-modified sugarcane variety, called CTC20BT, is safe.

The new variety developed by Centro de Tecnologia Canavieira (CTC) produces the Cry1Ab Bt protein to establish resistance to the sugarcane borer (Diatraea saccharalis), a major destructive pest in Brazil that causes damage and loss estimated at US$1 billion a year. The Bt protein found in CTC20BT, has a long history of safe use and has been used widely in global agriculture for over 20 years in biotechnology-derived crops like maize, and cotton, among others.

The sugar produced from the genetically modified (GM) sugarcane was as safe as sugar produced from conventional sugarcane and is compositionally identical to sugar produced from conventional varieties.

The US FDA focused its safety assessment on sugar because it is the main sugarcane-derived product imported to the US from Brazil. In addition to sugar refining, the Brazilian sugarcane sector uses sugarcane by products domestically to produce ethanol fuel for vehicles and to burn to generate electricity.

The recent US FDA approval followed a similar approval for sugar from Health Canada earlier this year. The sugarcane was first approved for cultivation in Brazil by CTNBio – Brazil's National Biosafety Technical Committee, in June 2017 following a detailed review process.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy